News
Clinical Trials Arena on MSN2d
Vir’s hepatitis B combo falls short in Phase II trialVir is holding off on advancing the combination therapy to Phase III trials until it secures a development partner.
Hosted on MSN4d
Arbutus Biopharma Showcases Promising Results for Hepatitis B Therapies at EASL Congress 2025WARMINSTER, PA — Arbutus Biopharma Corporation (Nasdaq: ABUS) recently presented compelling data on its investigational ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback